|
Getting your Trinity Audio player ready...
|
Over the course of the past year, Halberd Corporation (OTC:HALB) has emerged as one of the companies to have done considerable research in the field of healthcare. Yesterday, the company was in the news after it came up with an update with regards to the testing program for its patent-pending nasal spray at Mississippi State University.
The company announced that the university had managed to conclude the initial phase of the preclinical model that helped in setting up the baseline testing parameters and the endpoints for the study. The nasal spray in question is an innovative product that is meant for eliminating the inevitable effects of traumatic brain injury by directly targeting the antigens in cerebrospinal fluid.
The company is committed to addressing the crisis of traumatic brain injuries in the United States. As per the CDC, the economic impact of those injuries is high, and back in 2019; it was estimated to be as much as $2.4 trillion.
Additionally, there was $69 billion in work loss, $3.8 trillion in loss of quality of life, and $327 billion in medical care. In the announcement made on Tuesday, the company further noted that the university was ahead of schedule as it continued to quantify the testing parameters for the 2nd and the 3rd phases of testing of the nasal spray from Halberd.
The quantification process is expected to be concluded at some point in the near term. The innovative research into the whole thing would involve the development and application of testing mechanisms and parameters which would figure out the correlation between the degree of the head impact to the extent of resultant head injury.
The actual testing of the product would begin once those study endpoints and the testing parameters are figured out by the researchers.